STOCK TITAN

Quest Diagnostics Incorporated - $DGX STOCK NEWS

Welcome to our dedicated page for Quest Diagnostics Incorporated news (Ticker: $DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics Incorporated stock.

Quest Diagnostics Inc. (NYSE: DGX) is a leading provider of diagnostic testing, information, and services in the United States, enabling people to make informed health decisions. The company provides diagnostic insights derived from the world’s largest database of clinical lab results, which aids in identifying and treating diseases, promoting healthy behaviors, and improving healthcare management.

Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the United States. Its workforce of nearly 50,000 employees is dedicated to transforming lives by providing actionable diagnostic insights. The company offers the broadest test menu available, with over 3,000 different tests, and has a strong focus on cancer diagnostics, anatomic pathology, and interpretive consultations through its medical and scientific staff of approximately 900 M.D.s and Ph.D.s.

In recent years, Quest Diagnostics has been at the forefront of innovation in diagnostic testing. The company has significantly invested in AI and digital pathology to enhance the accuracy and efficiency of cancer diagnoses. A notable collaboration with PathAI aims to accelerate the adoption of digital and AI pathology technologies, thereby improving the quality, speed, and efficiency of diagnosing cancer and other diseases. This partnership includes the acquisition of PathAI Diagnostics’ state-of-the-art digitized laboratory in Memphis, Tennessee, which will serve as Quest’s AI and digital R&D and solutions center.

Financially, Quest Diagnostics has shown robust performance, with annual revenues reaching $7.4 billion in 2014. The company continues to strengthen its market presence through strategic acquisitions and partnerships, expanding its services and enhancing its capabilities in specialized pathology services. The integration of digital and AI technologies across its operations has improved quality, efficiency, and customer satisfaction, positioning Quest Diagnostics as a leader in the diagnostic services industry.

Quest Diagnostics' extensive clinical testing network includes roughly 2,300 patient service centers, numerous doctors' offices, and hospitals nationwide. The company also provides clinical trials testing, risk assessment services, and information technology solutions through its diagnostic solutions segment.

By leveraging its comprehensive diagnostic insights, Quest Diagnostics aims to empower individuals and healthcare providers to make informed decisions that lead to better health outcomes, ultimately contributing to a healthier world.

Rhea-AI Summary
Quest Diagnostics (DGX) collaborates with Community Health Centers to address current healthcare needs among underserved populations. The company surveyed FQHC leaders and found that staffing, nontraditional care services, and operational/financial concerns are the main challenges. Quest aims to support health centers in providing comprehensive care by breaking down affordability barriers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
-
Rhea-AI Summary
UDX (Universal DX) announces a strategic collaboration with Quest Diagnostics (DGX) and the initial closing of its series B financing of approximately $70 million. The collaboration aims to improve colorectal cancer screening in the United States by combining UDX's Signal-C® technology with Quest's expertise and national scale. The company plans to pursue FDA premarket approval for its colorectal cancer screening blood test and enroll patients in a 15,000-patient study. The test has shown 93% sensitivity for colorectal cancer detection and 54% sensitivity for detection of precancerous lesions at 92% specificity overall.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) has been awarded a multi-year contract by the CDC to assess the burden of hepatitis C virus (HCV) in the United States. The company will provide research consulting, laboratory testing, and data analytics services to generate diagnostics insights supporting population health strategy for hepatitis C.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) receives a 100% score on the Corporate Equality Index for the seventh consecutive year, showcasing its commitment to LGBTQ+ workplace equality. The company has 10 Employee Business Networks, including the Pride EBN, which has been promoting awareness, education, and advocacy for the LGBTQ+ community for over 20 years. The Inclusion and Diversity Council advises senior leaders on I&D goals and priorities, representing the needs and perspectives of diverse demographics across the company and communities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics (DGX) aims to expand its electric vehicle pilot project, secure ISO 14001 certification for additional lab locations, and transition 50% of its vehicle fleet to electric or hybrid engines by 2026. The company also achieved ISO 14001 certification for its esoteric laboratory facility in 2022 and is actively working on climate action, energy efficiency, and renewable energy procurement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics (DGX) Volunteers Bring Treats, No Tricks to Ronald McDonald House New York
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
Rhea-AI Summary
Quest Diagnostics (DGX) and Scipher Medicine announced a collaboration to expand patient access to diagnostic services for rheumatoid arthritis (RA). Quest will provide RNA extraction and sequencing services for Scipher's PrismRA test, aiming to predict patient response to TNF inhibitor therapy. This partnership aims to improve patient outcomes and reduce healthcare costs for RA treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics (DGX) Corporate Responsibility Report 2022: $15 million in corporate giving, 750,000 donated or discounted test requisitions, and $300,000 in matched employee donations
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics (DGX) aims to deliver empathetic, high-quality, and convenient individualized care. In 2022, the company strengthened its approach to patient-centered care through development programs and technology enhancements. This included new staff training and development programs, content and training through Everyday Excellence and Everyday Equity programs, collaboration with The Arnold P. Gold Foundation to train frontline employees in humanistic patient engagement, adoption of Franklin Covey's Speed of Trust® Program, and enhancing the patient experience using technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
none
Rhea-AI Summary
UDX - Universal DX Announces Strategic Collaboration with Quest Diagnostics and $70 Million Series B Financing for Colorectal Cancer Screening Blood Test
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
none

FAQ

What does Quest Diagnostics do?

Quest Diagnostics provides diagnostic testing, information, and services that help healthcare providers and patients make informed health decisions. The company offers a broad range of tests and diagnostic insights derived from the world’s largest database of clinical lab results.

How many people does Quest Diagnostics serve annually?

Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the United States each year.

What are some recent achievements of Quest Diagnostics?

Recently, Quest Diagnostics has partnered with PathAI to enhance its AI and digital pathology capabilities. The acquisition of PathAI Diagnostics' digital laboratory will serve as a new AI and digital R&D center, improving cancer diagnosis quality and efficiency.

What kind of tests does Quest Diagnostics offer?

Quest Diagnostics offers over 3,000 different tests, including clinical testing, anatomic pathology, esoteric testing, and substance abuse testing.

What is the company's approach to innovation?

Quest Diagnostics focuses on incorporating AI and digital technologies into its diagnostic services to enhance accuracy, efficiency, and accessibility of its offerings. The company also pilots new technologies and expands its capabilities through strategic partnerships and acquisitions.

How extensive is Quest Diagnostics' clinical testing network?

Quest Diagnostics operates an extensive clinical testing network with approximately 2,300 patient service centers, as well as numerous doctor’s offices and hospitals across the United States.

What role do partnerships play at Quest Diagnostics?

Partnerships, such as the recent collaboration with PathAI, play a crucial role in Quest Diagnostics' strategy to integrate advanced technologies and expand its capabilities in specialized diagnostic services.

How does Quest Diagnostics contribute to healthcare management?

Quest Diagnostics provides diagnostic insights that help identify and treat diseases, inspire healthy behaviors, and improve healthcare management. These insights support more informed decision-making by both patients and healthcare providers.

What are the company’s future plans?

Quest Diagnostics plans to continue expanding its capabilities in AI and digital pathology, enhance its clinical testing services, and maintain its leadership in diagnostic information services. The company aims to leverage its diagnostic insights to empower better healthcare outcomes globally.

How does Quest Diagnostics ensure the quality of its services?

Quest Diagnostics employs nearly 50,000 dedicated professionals, including about 900 M.D.s and Ph.D.s, and integrates cutting-edge technology and rigorous quality control measures across its operations to ensure high-quality diagnostic services.

Quest Diagnostics Incorporated

NYSE:DGX

DGX Rankings

DGX Stock Data

15.44B
110.06M
0.44%
92.96%
2.43%
Medical Laboratories
Health Care and Social Assistance
Link
United States of America
SECAUCUS